Bulk Manufacturer of Controlled Substances Application: Purisys, LLC, 41244 [2020-14781]
Download as PDF
<![CDATA[
41244
Federal Register / Vol. 85, No. 132 / Thursday, July 9, 2020 / Notices
to the docket number (‘‘Docket No.
3466’’) in a prominent place on the
cover page and/or the first page. (See
Handbook for Electronic Filing
Procedures, Electronic Filing
Procedures 1.) Please note the
Secretary’s Office will accept only
electronic filings during this time.
Filings must be made through the
Commission’s Electronic Document
Information System (EDIS, https://
edis.usitc.gov). No in-person paperbased filings or paper copies of any
electronic filings will be accepted until
further notice. Persons with questions
regarding filing should contact the
Secretary at EDIS3Help@usitc.gov.
Any person desiring to submit a
document to the Commission in
confidence must request confidential
treatment. All such requests should be
directed to the Secretary to the
Commission and must include a full
statement of the reasons why the
Commission should grant such
treatment. See 19 CFR 201.6. Documents
for which confidential treatment by the
Commission is properly sought will be
treated accordingly. All information,
including confidential business
information and documents for which
confidential treatment is properly
sought, submitted to the Commission for
purposes of this Investigation may be
disclosed to and used: (i) By the
Commission, its employees and Offices,
and contract personnel (a) for
developing or maintaining the records
of this or a related proceeding, or (b) in
internal investigations, audits, reviews,
and evaluations relating to the
programs, personnel, and operations of
the Commission including under 5
U.S.C. Appendix 3; or (ii) by U.S.
government employees and contract
personnel,2 solely for cybersecurity
purposes. All nonconfidential written
submissions will be available for public
inspection at the Office of the Secretary
and on EDIS.3
This action is taken under the
authority of section 337 of the Tariff Act
of 1930, as amended (19 U.S.C. 1337),
and of §§ 201.10 and 210.8(c) of the
Commission’s Rules of Practice and
Procedure (19 CFR 201.10, 210.8(c)).
jbell on DSKJLSW7X2PROD with NOTICES
By order of the Commission.
1 Handbook for Electronic Filing Procedures:
https://www.usitc.gov/documents/handbook_on_
filing_procedures.pdf.
2 All contract personnel will sign appropriate
nondisclosure agreements.
3 Electronic Document Information System
(EDIS): https://edis.usitc.gov.
VerDate Sep<11>2014
16:40 Jul 08, 2020
Jkt 250001
Issued: July 6, 2020.
William Bishop,
Supervisory Hearings and Information
Officer.
[FR Doc. 2020–14802 Filed 7–8–20; 8:45 am]
BILLING CODE 7020–02–P
[Docket No. DEA–674]
Bulk Manufacturer of Controlled
Substances Application: Purisys, LLC
Notice of application.
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before September 8, 2020.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
DATES:
In
accordance with 21 CFR 1301.33(a), this
is notice that on May 14, 2020, Purisys,
LLC, 1550 Olympic Drive Athens,
Georgia 30601–1602, applied to be
registered as a bulk manufacturer of the
following basic class(es) of controlled
substances:
SUPPLEMENTARY INFORMATION:
Drug
code
Controlled substance
Gamma-hydroxybutyic acid .....
Marihuana Extract ....................
Marihuana ................................
Tetrahydrocannabinols ............
Codeine-N-Oxide .....................
Dihydromorphine ......................
Hydromorphinol ........................
Nabilone ...................................
Codeine ....................................
Dihydrocodeine ........................
Oxycodone ...............................
Hydromorphone .......................
Hydrocodone ............................
Levorphanol .............................
Morphine ..................................
2010
7350
7360
7370
9053
9145
9301
7379
9050
9120
9143
9150
9193
9220
9300
Schedule
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
The company plans to manufacture
7360, 7370, and 7379 as bulk active
pharmaceutical ingredients and
manufacture the remaining above-listed
controlled substances as analytical
reference standards for distribution to
customers. The company also plans to
use these substances for lab scale
research and development activities. In
reference to drug codes 7360 and 7370,
the company plans to bulk manufacture
these as synthetic. No other activities for
Frm 00019
Fmt 4703
[FR Doc. 2020–14781 Filed 7–8–20; 8:45 am]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
PO 00000
William T. McDermott,
Assistant Administrator.
BILLING CODE P
DEPARTMENT OF JUSTICE
ACTION:
these drug codes are authorized for this
registration.
Sfmt 4703
Notice of Lodging of Proposed
Consent Decree Under the Resource
Conservation and Recovery Act
On July 1, 2020, the Department of
Justice lodged a proposed Consent
Decree with the United States District
Court for the Eastern District of
Wisconsin in the lawsuit entitled
United States v. Waste Management of
Wisconsin, Inc., Civil Action No. 20–cv–
993.
The United States brought this case
under the Resource Conservation and
Recovery Act (‘‘RCRA’’), 42 U.S.C. 6901
et seq. The Complaint alleges that Waste
Management improperly disposed of
hazardous waste at the Metro Recycling
and Disposal Facility in Franklin,
Wisconsin. The Consent Decree requires
Waste Management to pay a civil
penalty of $232,000, implement a
program of groundwater and leachate
testing, and enforce policies designed to
ensure future compliance with RCRA.
The Consent Decree would resolve the
United States’ RCRA claims in the
complaint and other potential RCRA
claims based on the same type of waste
addressed in the complaint.
The publication of this notice opens
a period for public comment on the
Consent Decree. Comments should be
addressed to the Assistant Attorney
General, Environment and Natural
Resources Division, and should refer to
United States v. Waste Management of
Wisconsin, Inc., D.J. Ref. No. 90–7–1–
11093. All comments must be submitted
no later than thirty (30) days after the
publication date of this notice.
Comments may be submitted either by
email or by mail:
To submit
comments:
Send them to:
By email .......
pubcomment-ees.enrd@
usdoj.gov
Assistant Attorney General,
U.S. DOJ—ENRD, P.O.
Box 7611, Washington, DC
20044–7611.
By mail .........
During the public comment period,
the Consent Decree may be examined
and downloaded at this Justice
Department website: https://
www.justice.gov/enrd/consent-decrees.
We will provide a paper copy of the
E:\FR\FM\09JYN1.SGM
09JYN1
]]>Agencies
[Federal Register Volume 85, Number 132 (Thursday, July 9, 2020)]
[Notices]
[Page 41244]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-14781]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-674]
Bulk Manufacturer of Controlled Substances Application: Purisys,
LLC
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may file written comments on or objections to
the issuance of the proposed registration on or before September 8,
2020.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this
is notice that on May 14, 2020, Purisys, LLC, 1550 Olympic Drive
Athens, Georgia 30601-1602, applied to be registered as a bulk
manufacturer of the following basic class(es) of controlled substances:
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Gamma-hydroxybutyic acid................ 2010 I
Marihuana Extract....................... 7350 I
Marihuana............................... 7360 I
Tetrahydrocannabinols................... 7370 I
Codeine-N-Oxide......................... 9053 I
Dihydromorphine......................... 9145 I
Hydromorphinol.......................... 9301 I
Nabilone................................ 7379 II
Codeine................................. 9050 II
Dihydrocodeine.......................... 9120 II
Oxycodone............................... 9143 II
Hydromorphone........................... 9150 II
Hydrocodone............................. 9193 II
Levorphanol............................. 9220 II
Morphine................................ 9300 II
------------------------------------------------------------------------
The company plans to manufacture 7360, 7370, and 7379 as bulk
active pharmaceutical ingredients and manufacture the remaining above-
listed controlled substances as analytical reference standards for
distribution to customers. The company also plans to use these
substances for lab scale research and development activities. In
reference to drug codes 7360 and 7370, the company plans to bulk
manufacture these as synthetic. No other activities for these drug
codes are authorized for this registration.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2020-14781 Filed 7-8-20; 8:45 am]
BILLING CODE P
